Latest news with #StuartRay
Yahoo
20-04-2025
- Entertainment
- Yahoo
Southampton students livestream prestigious Royal Television Awards
A group of students from a Southampton university livestreamed a prestigious television awards night. Some nine television production students from Southampton Solent University were tasked with delivering a professional broadcast for the 2025 Royal Television Society (RTS) Southern Awards on March 25. The awards, which celebrate the best in local television, were attended by industry professionals from ITV Meridian, BBC South, and Woodcut Media. The students were approached by RTS Chair, Stuart Ray, to provide the live stream for the annual event. They were responsible for every aspect of the production, from liaising with RTS and conducting location recces to working with lighting and sound professionals. READ MORE: Student team recognised for 'outstanding achievement' in live broadcast project The team used the university's state-of-the-art equipment, including five Sony PMW-400 cameras, a Blackmagic Atem Vision Mixer, and streaming iMacs, to create a high-quality broadcast. They used fixed tripod cameras for the main stage, wireless handhelds to capture live audience reactions and winners' walk-ups, and on-stage graphics monitors to help presenters stay in sync with the show flow. Final-year student Alex Dobson, who was the unit manager for the broadcast, said: "The most challenging part was the last-minute switch in our room position. "We had to rethink our whole setup, check for power availability, and completely change our streaming approach. "It was a moment that really tested our teamwork and problem-solving under pressure." Despite the challenges, the team was ready ahead of schedule, with enough time to fully test everything before going live. READ MORE: Solent University takes home several awards from major student TV event Senior lecturer Kate O'Driscoll said: "What makes Solent stand out is its emphasis on hands-on, real-world learning. "These live projects are central to the curriculum, giving students the chance to work directly with real clients, build their CVs, and showcase their skills to professionals, before they graduate. "Alex and the rest of the team did a great job and should be proud of the enthusiasm, creativity, and professionalism that they brought to the project." Alex, who hopes to join an outside broadcast company as a camera operator and broadcast engineer after graduation, said: "These projects are essential. "They let me prove that I can handle these jobs at a professional level. "I feel confident stepping into the industry knowing I've already done it - with the support and guidance of my course."
Yahoo
15-04-2025
- Health
- Yahoo
New antibiotic could treat drug-resistant gonorrhea: Study
A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a new study published Monday in The Lancet. The drug, called gepotidacin, works by preventing bacteria from replicating in the body and was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and in girls 12 years and older. If approved to treat gonorrhea, it will be the newest antibiotic to treat the sexually transmitted infection since the 1990s. The drug is manufactured by the pharmaceutical company GSK and is sold under the name Blujepa. After reaching a historic low in 2009, cases of gonorrhea in the United States steadily increased until 2021 and have slowly declined since then, according to the Centers for Disease Control and Prevention (CDC). Still, gonorrhea is the second most common sexually transmitted infection in the country with, 601,319 reported cases in 2023, according to the agency. Gonorrhea, and other sexually transmitted infections, are becoming more difficult to treat as they become increasingly more resistant to existing antibiotics. The CDC currently recommends providers treat gonorrhea with a 500 mg injection of the antibiotic ceftriaxone. The agency updated its treatment guidelines in 2023, directing providers to administer a higher dose of the drug to combat antibiotic resistance. Justin Gill, an urgent care nurse practitioner and president of the Washington State Nurses Association, told The Hill that he frequently treats gonorrhea and has encountered cases of the infection that are resistant to ceftriaxone. 'There are only a handful of antibiotics that are available as backup options,' he said. 'The development of new antibiotics has been slow, but federal investment in new and emerging antibiotic options is necessary before resistant strains of gonorrhea expand further.' If left untreated, gonorrhea can cause serious health complications that can lead to infertility in both men and women, and it can increase the odds of contracting and passing HIV, according to the CDC. The trial of more than 620 people showed gepotidacin was about 92 percent effective in treating the infection among those who took the drug twice a day. Meanwhile, a regimen of combination ceftriaxone and azithromycin was about 91 percent effective. Stuart Ray, an infectious disease professor at Johns Hopkins University School of Medicine who did not take part in the study, said that any progress in safely and effectively treating gonorrhea is 'exciting.' He added that the fact that the drug can be administered in pill form makes it 'attractive.' 'In general, it's very exciting to see a late-stage trial for a new antimicrobial for a thorny problem like gonorrhea,' he said. 'I think it's very exciting to see data and progression of an agent this far down the path.' Ray said that of the more than 600 trial participants, less than 10 percent were women. 'We have to be careful about making conclusions about subgroups that may have been somewhat underrepresented.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
14-04-2025
- Health
- The Hill
New antibiotic could treat drug-resistant gonorrhea, study says
A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a new study published Monday in The Lancet. The drug, called gepotidacin, works by preventing bacteria from replicating in the body and was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and in girls 12 years and older. If approved to treat gonorrhea, it will be the newest antibiotic to treat the sexually transmitted infection since the 1990s. The drug is manufactured by the pharmaceutical company GSK and is sold under the name Blujepa. After reaching a historic low in 2009, cases of gonorrhea in the United States steadily increased until 2021 and have slowly declined since then, according to the Centers for Disease Control and Prevention (CDC). Still, gonorrhea is the second most common sexually transmitted infection in the country with 601,319 reported cases in 2023, according to the agency. Gonorrhea, and other STIs, are becoming more difficult to treat as they become increasingly more resistant to existing antibiotics. The CDC currently recommends providers treat gonorrhea with a 500 mg injection of the antibiotic ceftriaxone. The agency updated its treatment guidelines in 2023, directing providers to administer a higher dose of the drug to combat antibiotic resistance. Justin Gill, an urgent care nurse practitioner and president of the Washington State Nurses Association, told The Hill that he frequently treats gonorrhea and has encountered cases of the infection that are resistant to ceftriaxone. 'There are only a handful of antibiotics that are available as backup options,' he said. 'The development of new antibiotics has been slow, but federal investment in new and emerging antibiotic options is necessary before resistant strains of gonorrhea expand further.' If left untreated, gonorrhea can cause serious health complications which can lead to infertility in both men and women, as well as increasing the odds of contracting and passing HIV, according to the CDC. The trial of more than 620 people showed gepotidacin was about 92 percent effective in treating the infection among those who took the drug twice a day. Meanwhile, a regimen of combination ceftriaxone and azithromycin was about 91 percent effective. Stuart Ray, an infectious disease professor at Johns Hopkins University School of Medicine who did not take part in the study, said that any progress in safely and effectively treating gonorrhea is 'exciting.' He added that the fact that the drug can be administered in pill form makes it 'attractive.' 'In general, it's very exciting to see a late-stage trial for a new antimicrobial for a thorny problem like gonorrhea,' he said. 'I think it's very exciting to see data and progression of an agent this far down the path.' Ray said that of the more than 600 trial participants, less than 10 percent were women. 'We have to be careful about making conclusions about subgroups that may have been somewhat underrepresented.'
